ZMapp

ZMapp
Adenosine · CC BY-SA 3.0 · source
Name	ZMapp
Type	experimental monoclonal antibody cocktail
Target	Ebola virus
Legal status	experimental
Routes of administration	intravenous
Discovered by	Mapp Biopharmaceutical
Developer	Mapp Biopharmaceutical; produced with partners

ZMapp is an experimental monoclonal antibody cocktail developed as a therapeutic candidate against Ebola virus infections during the 2014–2016 West African Ebola epidemic. It was developed by a collaboration including private companies and academic groups and was used experimentally in emergency situations involving healthcare workers and humanitarian personnel from countries such as United States, United Kingdom, Sierra Leone, Liberia, and Guinea. The candidate attracted global attention from institutions including the World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, and governments confronting outbreaks.

Background and Development

ZMapp traces to earlier monoclonal antibody research at institutions such as Scripps Research, Public Health Agency of Canada, Defence Science and Technology Laboratory, and Mapp Biopharmaceutical. The cocktail’s lineage involves antibodies discovered during studies of Ebolavirus species including Zaire ebolavirus and efforts by teams at LeafBio, Kent State University, University of Texas Medical Branch, and National Microbiology Laboratory (Canada). Funding and coordination came from entities such as the U.S. Department of Defense, U.S. Army Medical Research Institute of Infectious Diseases, Wellcome Trust, Gavi, the Vaccine Alliance, and philanthropic actors including the Bill & Melinda Gates Foundation. The product emerged amid responses involving international organizations like Médecins Sans Frontières, International Federation of Red Cross and Red Crescent Societies, and national public health agencies responding to the 2014 West Africa Ebola epidemic and later events in Democratic Republic of the Congo.

Composition and Mechanism of Action

The therapeutic is a combination of chimeric and humanized monoclonal antibodies originally derived from immunized animals and human survivors, with contributions from labs such as Scripps Research Institute, Defense Advanced Research Projects Agency, and Johns Hopkins University. The antibodies target surface glycoproteins of Ebolavirus similar to targets studied in Marburg virus research at institutions like Harvard Medical School and Pasteur Institute. The mechanism involves antibody-mediated neutralization, opsonization, and blockade of viral entry, paralleling immunotherapeutic strategies used against pathogens studied at Columbia University, Stanford University School of Medicine, Yale School of Medicine, University of Pennsylvania, and Imperial College London. Preclinical models in biosafety facilities such as Rocky Mountain Laboratories and Centers for Disease Control and Prevention high-containment labs demonstrated protection in nonhuman primates at research centers including Oregon Health & Science University and Wake Forest School of Medicine.

Preclinical and Clinical Studies

Preclinical efficacy was reported in studies conducted at National Institutes of Health facilities and partner laboratories including USAMRIID and Public Health Agency of Canada. During the 2014 West Africa Ebola epidemic, emergency use involved patients evacuated to hospitals such as Emory University Hospital, University of Nebraska Medical Center, Royal Free Hospital, and Kennedy Krieger Institute collaborators, with clinicians from Doctors Without Borders and Centers for Disease Control and Prevention advising. Clinical evaluation included trials coordinated by organizations like WHO, National Institutes of Health, Pan American Health Organization, and academic centers such as Oxford University and University College London. Study designs referenced adaptive trial methods used in trials like those at Emanuel Miller Centre and statistical approaches from groups at London School of Hygiene & Tropical Medicine. Results prompted further investigations in outbreak settings overseen by national regulators including Food and Drug Administration and European Medicines Agency.

Manufacturing and Distribution

Manufacturing involved biopharmaceutical firms such as Mapp Biopharmaceutical, contract manufacturers, and academic spin-offs including LeafBio and facilities in San Diego, Oakland, and international partners in Canada and Netherlands. Production utilized plant-based expression platforms inspired by work at Large-scale Bioproduction groups and companies like Kentucky Bioprocessing and technologies similar to those developed at Fraunhofer Institute. Distribution during outbreaks required coordination with logistical organizations like United Nations Office for the Coordination of Humanitarian Affairs, International Committee of the Red Cross, Airbus, United Airlines, and national health ministries of Sierra Leone, Guinea, and Liberia. Supply constraints led to prioritization guided by bodies such as World Health Organization emergency committees and ethical panels hosted by Harvard T.H. Chan School of Public Health and Oxford Vaccine Group.

Regulatory Status and Approvals

Regulatory review involved agencies including the U.S. Food and Drug Administration, European Medicines Agency, Health Canada, and national authorities in Sierra Leone, Liberia, and Guinea. The candidate was administered under emergency investigational protocols, compassionate use provisions similar to those overseen by FDA Expanded Access Program and trials analogous to those managed by NIH Clinical Center. International guidance from World Health Organization on experimental therapies during outbreaks influenced policy decisions used by ministries of health and advisory committees including panels from Wellcome Trust and Coalition for Epidemic Preparedness Innovations.

Controversies and Ethical Considerations

Use of the experimental therapy raised debates involving bioethicists from Nuffield Council on Bioethics, Georgetown University, Yale University, and Johns Hopkins Berman Institute of Bioethics about equitable access, consent, and prioritization among populations in West Africa and expatriate healthcare workers from United States, United Kingdom, Canada, and Spain. Allocation and transparency controversies involved international NGOs such as Médecins Sans Frontières and policy discussions at World Health Organization emergency ethics committees. Manufacturing limitations and intellectual property discussions included stakeholders such as Mapp Biopharmaceutical, academic licensors from Scripps Research, and funders including Wellcome Trust and Bill & Melinda Gates Foundation, paralleling debates seen in cases like oseltamivir and vaccine access in H1N1 influenza pandemic discussions. Legal and media scrutiny involved outlets based in New York City, Washington, D.C., London, and Paris and prompted scholarly analysis from universities including Harvard, Oxford, Cambridge, and King's College London.

Category:Antiviral drugs